pre-miRNA Information | |
---|---|
pre-miRNA | hsa-mir-1231 |
Genomic Coordinates | chr1: 201808611 - 201808702 |
Synonyms | MIRN1231, hsa-mir-1231, MIR1231 |
Description | Homo sapiens miR-1231 stem-loop |
Comment | None |
RNA Secondary Structure | |
Associated Diseases |
Mature miRNA Information | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mature miRNA | hsa-miR-1231 | |||||||||||||||
Sequence | 5| GUGUCUGGGCGGACAGCUGC |24 | |||||||||||||||
Evidence | Experimental | |||||||||||||||
Experiments | Cloned | DRVs in miRNA |
|
|||||||||||||
SNPs in miRNA |
|
|||||||||||||||
Putative Targets |
Gene Information | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene Symbol | MAPKAPK2 | ||||||||||||||||||||
Synonyms | MAPKAP-K2, MK-2, MK2 | ||||||||||||||||||||
Description | mitogen-activated protein kinase-activated protein kinase 2 | ||||||||||||||||||||
Transcript | NM_004759 | ||||||||||||||||||||
Other Transcripts | NM_032960 | ||||||||||||||||||||
Expression | |||||||||||||||||||||
Putative miRNA Targets on MAPKAPK2 | |||||||||||||||||||||
3'UTR of MAPKAPK2 (miRNA target sites are highlighted) |
>MAPKAPK2|NM_004759|3'UTR 1 GCAGAGGATTCTGTGTTCCTGTCCAAACTCAGTGCTGTTTCTTAGAATCCTTTTATTCCCTGGGTCTCTAATGGGACCTT 81 AAAGACCATCTGGTATCATCTTCTCATTTTGCAGAAGAGAAACTGAGGCCCAGAGGCGGAGGGCAGTCTGCTCAAGGTCA 161 CGCAGCTGGTGACTGGTTGGGGCAGACCGGACCCAGGTTTCCTGACTCCTGGCCCAAGTCTCTTCCTCCTATCCTGCGGG 241 ATCACTGGGGGGCTCTCAGGGAACAGCAGCAGTGCCATAGCCAGGCTCTCTGCTGCCCAGCGCTGGGGTGAGGCTGCCGT 321 TGTCAGCGTGGACCACTAACCAGCCCGTCTTCTCTCTCTGCTCCCACCCCTGCCGCCCTCACCCTGCCCTTGTTGTCTCT 401 GTCTCTCACGTCTCTCTTCTGCTGTCTCTCCTACCTGTCTTCTGGCTCTCTCTGTACCCTTCCTGGTGCTGCCGTGCCCC 481 CAGGAGGAGATGACCAGTGCCTTGGCCACAATGCGCGTTGACTACGAGCAGATCAAGATAAAAAAGATTGAAGATGCATC 561 CAACCCTCTGCTGCTGAAGAGGCGGAAGAAAGCTCGGGCCCTGGAGGCTGCGGCTCTGGCCCACTGAGCCACCGCGCCCT 641 CCTGCCCACGGGAGGACAAGCAATAACTCTCTACAGGAATATATTTTTTAAACGAAGAGACAGAACTGTCCACATCTGCC 721 TCCTCTCCTCCTCAGCTGCATGGAGCCTGGAACTGCATCAGTGACTGAATTCTGCCTTGGTTCTGGCCACCCCAGAGTGG 801 GAGAGGCTGGGAGGTTGGGAGGCTGTGGAGAGAAGTGAGCAAGGTGCTCTTGAACCTGTGCTCATTTTGCAATTTTATCA 881 GTAATTTGACTTAGAGTTTTTACGAAACCTCTTTTGTTGTCCTTGCCCCACTCCTCTCCACCAGACGCCTTCCTCTCTGG 961 ATACTGCAAAGGCTTGTGGTTTGTTAGAGGGTATTTGTGGAAACTGTCATAGGGATTGTCCCTGTGTTGTCCCATCTGCC 1041 CTCCCTGTTTCTCCACAACAGCCTGGGGTTGTCCCCGCTGGCTCACGCGTTCTGGGAGCTCAAGGCCACCTTGGAGGAGG 1121 ATGCCACGCACTTCCTCTCTCGGAGCCCTCAGACATCTCCAGTGTGCCAGACAAATAGGAGTGAGTGTATGTGTGTGTGT 1201 GTGTGTGTGTGTGTGCACACGTGTGTATGAGTGCGCAGATCTGTGCCTGGGATCGTGCATTTGAGGGGCCAGGGGCAGGC 1281 AGGGCTGCAGAGGGAGACGGCCCTGCTGGGGCTTAGGAACCTTCTCCCTTCTTGGGTCTGCCCTGCCCATACTGAGCCTG 1361 CCAAAGTGCCTGGGAAGCCCACCCAGATTCTGAAACAGGCCCTCTGTGGCCTGTCTCTATTAGCTGGGTTCCGGGAGGCA 1441 GAGAGGAGTGACCGGGCACTGGCACTGCGATCAGGAAGACTGGACCCCCAGCCCCCAGGGCCCCCCTCCCCCCACTTAGT 1521 GCTGGTCCTAGGTCCTCTGAGGCACTCATCTACTGAATGACCTCTCTACTTCCCCTTCTTGCCATTATTAACCCATTTTT 1601 GTTTATTTTCCTTAAATTTTTAGCCATTTCTCCATGGGCCACCGCCCAGCTCATGTAGGTGAGCCTGGGCAGCTTCTGTT 1681 GGCAGAGCTTTTGCATTTCCTGTGTTTGTCCTGGGTTCTGGGGCATCAGCCAGCTACCCCTTGTGGGCAAAGGCAGGGCC 1761 ACTTTTGAAGTCTTCCCTCAGATTTCCATTGTGTGGCCTGGTGGGTCAGGGGGAGTCTTTGCACCAAAGATGTCCTGACT 1841 TTGCCCCCTTGCCCATCAGCCATTTGCCATCACCCCAAACAACTCAGCTTCGGGGCCGGTGAGGGGAGGGGCCTCCCCCA 1921 GCACAGATGAGGAGCAGCTGGGGTAGGCTGTCTGTGCCATGGCCCCCCACTCCCCCTTCCCTTGGAGGGAGAGGTGGCAG 2001 GAATACTTCACCTTTCCTCTCCCTCAGGGGCAGGTGGTGGAGGGGCGCCCAGGGTCGTCTTTGTGTATGGGGGAAGGCGC 2081 TGGGTGCCTGCAGCGCCTCCCTTGTCTCAGATGGTGTGTCCAGCACTCGATTGTTGTAAACTGTTGTTTTGTATGAGCGA 2161 AATTGTCTTTACTAAACAGATTTAATAGTTGAGAAAAAAAAAAAAAAAAAA Target sites
Provided by authors
Predicted by miRanda
DRVs
SNPs
DRVs & SNPs
|
||||||||||||||||||||
miRNA-target interactions (Predicted by miRanda) |
|
||||||||||||||||||||
DRVs in gene 3'UTRs | |||||||||||||||||||||
SNPs in gene 3'UTRs |
Experimental Support 1 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Conditions | HEK293S |
Location of target site | 3'UTR |
Tools used in this research | TargetScan , miRTarCLIP , Piranha |
Original Description (Extracted from the article) |
...
HITS-CLIP data was present in GSM1084064. RNA binding protein: AGO2. Condition:CLIP_noemetine_AbnovaAb
HITS-CLIP data was present in GSM1084069. RNA binding protein: AGO2. Condition:CLIP_emetine_SigmaAb
HITS-CLIP data was present in GSM1084072. RNA binding protein: AGO2. Condition:CLIP_nohippuristanol_rep1_AbnovaAb
HITS-CLIP data was present in GSM1084073. RNA binding protein: AGO2. Condition:CLIP_hippuristanol_rep1_AbnovaAb
HITS-CLIP data was present in GSM1084076. RNA binding protein: AGO2. Condition:CLIP_nohippuristanol_rep1_SigmaAb
HITS-CLIP data was present in GSM1084080. RNA binding protein: AGO2. Condition:CLIP_nohippuristanol_rep2_SantaCruzAb
... - Karginov FV; Hannon GJ, 2013, Genes & development. |
Article |
- Karginov FV; Hannon GJ - Genes & development, 2013
When adapting to environmental stress, cells attenuate and reprogram their translational output. In part, these altered translation profiles are established through changes in the interactions between RNA-binding proteins and mRNAs. The Argonaute 2 (Ago2)/microRNA (miRNA) machinery has been shown to participate in stress-induced translational up-regulation of a particular mRNA, CAT-1; however, a detailed, transcriptome-wide understanding of the involvement of Ago2 in the process has been lacking. Here, we profiled the overall changes in Ago2-mRNA interactions upon arsenite stress by cross-linking immunoprecipitation (CLIP) followed by high-throughput sequencing (CLIP-seq). Ago2 displayed a significant remodeling of its transcript occupancy, with the majority of 3' untranslated region (UTR) and coding sequence (CDS) sites exhibiting stronger interaction. Interestingly, target sites that were destined for release from Ago2 upon stress were depleted in miRNA complementarity signatures, suggesting an alternative mode of interaction. To compare the changes in Ago2-binding patterns across transcripts with changes in their translational states, we measured mRNA profiles on ribosome/polysome gradients by RNA sequencing (RNA-seq). Increased Ago2 occupancy correlated with stronger repression of translation for those mRNAs, as evidenced by a shift toward lighter gradient fractions upon stress, while release of Ago2 was associated with the limited number of transcripts that remained translated. Taken together, these data point to a role for Ago2 and the mammalian miRNAs in mediating the translational component of the stress response.
LinkOut: [PMID: 23824327]
|
Experimental Support 2 for Functional miRNA-Target Interaction | |||||||
---|---|---|---|---|---|---|---|
miRNA:Target | ---- | ||||||
Validation Method |
|
||||||
Conditions | Cardiac Tissues | ||||||
Location of target site | 3'UTR | ||||||
Tools used in this research | TargetScan , miRTarCLIP , Piranha | ||||||
Original Description (Extracted from the article) |
...
HITS-CLIP data was present in GSM2202476. RNA binding protein: AGO2. Condition:S1_LV_54yo_Male_AGO2_bound_RNA
... - Spengler RM; Zhang X; Cheng C; McLendon JM; et al., 2016, Nucleic acids research. |
||||||
miRNA-target interactions (Provided by authors) |
|
||||||
Article |
Elucidation of transcriptome-wide microRNA binding sites in human cardiac tissues by Ago2 HITS-CLIP.
- Spengler RM; Zhang X; Cheng C; McLendon JM; et al.- Nucleic acids research, 2016
MicroRNAs (miRs) have emerged as key biological effectors in human health and disease. These small noncoding RNAs are incorporated into Argonaute (Ago) proteins, where they direct post-transcriptional gene silencing via base-pairing with target transcripts. Although miRs have become intriguing biological entities and attractive therapeutic targets, the translational impacts of miR research remain limited by a paucity of empirical miR targeting data, particularly in human primary tissues. Here, to improve our understanding of the diverse roles miRs play in cardiovascular function and disease, we applied high-throughput methods to globally profile miR:target interactions in human heart tissues. We deciphered Ago2:RNA interactions using crosslinking immunoprecipitation coupled with high-throughput sequencing (HITS-CLIP) to generate the first transcriptome-wide map of miR targeting events in human myocardium, detecting 4000 cardiac Ago2 binding sites across >2200 target transcripts. Our initial exploration of this interactome revealed an abundance of miR target sites in gene coding regions, including several sites pointing to new miR-29 functions in regulating cardiomyocyte calcium, growth and metabolism. Also, we uncovered several clinically-relevant interactions involving common genetic variants that alter miR targeting events in cardiomyopathy-associated genes. Overall, these data provide a critical resource for bolstering translational miR research in heart, and likely beyond.
LinkOut: [PMID: 27418678]
|
CLIP-seq Support 1 for dataset GSM1084064 | |
---|---|
Method / RBP | HITS-CLIP / AGO2 |
Cell line / Condition | HEK293S / CLIP_noemetine_AbnovaAb |
Location of target site | ENST00000294981.4 | 3UTR | AAUAGGAGUGAGUGUAUGUGUGUGUGUGUGUGUGUGU |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 23824327 / GSE44404 |
CLIP-seq Viewer | Link |
CLIP-seq Support 2 for dataset GSM1084069 | |
---|---|
Method / RBP | HITS-CLIP / AGO2 |
Cell line / Condition | HEK293S / CLIP_emetine_SigmaAb |
Location of target site | ENST00000294981.4 | 3UTR | AAUAGGAGUGAGUGUAU |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 23824327 / GSE44404 |
CLIP-seq Viewer | Link |
CLIP-seq Support 3 for dataset GSM1084072 | |
---|---|
Method / RBP | HITS-CLIP / AGO2 |
Cell line / Condition | HEK293S / CLIP_nohippuristanol_rep1_AbnovaAb |
Location of target site | ENST00000294981.4 | 3UTR | AAUAGGAGUGAGUGUAUGUGUGUGUGUGUGUGUGU |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 23824327 / GSE44404 |
CLIP-seq Viewer | Link |
CLIP-seq Support 4 for dataset GSM1084073 | |
---|---|
Method / RBP | HITS-CLIP / AGO2 |
Cell line / Condition | HEK293S / CLIP_hippuristanol_rep1_AbnovaAb |
Location of target site | ENST00000294981.4 | 3UTR | AAUAGGAGUGAGUGUAUGUGUGUGUGUGUGU |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 23824327 / GSE44404 |
CLIP-seq Viewer | Link |
CLIP-seq Support 5 for dataset GSM1084076 | |
---|---|
Method / RBP | HITS-CLIP / AGO2 |
Cell line / Condition | HEK293S / CLIP_nohippuristanol_rep1_SigmaAb |
Location of target site | ENST00000294981.4 | 3UTR | AAUAGGAGUGAGUGUAUGUGU |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 23824327 / GSE44404 |
CLIP-seq Viewer | Link |
MiRNA-Target Expression Profile | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
MiRNA-Target Expression Profile (TCGA) | |||||||
---|---|---|---|---|---|---|---|
|
37 hsa-miR-1231 Target Genes:
Functional analysis:
ID | Target | Description | Validation methods | |||||||||
Strong evidence | Less strong evidence | |||||||||||
MIRT075228 | PHF13 | PHD finger protein 13 | 2 | 6 | ||||||||
MIRT266936 | HDGF | heparin binding growth factor | 2 | 6 | ||||||||
MIRT441394 | SOX5 | SRY-box 5 | 2 | 2 | ||||||||
MIRT446329 | ATP5C1 | ATP synthase, H+ transporting, mitochondrial F1 complex, gamma polypeptide 1 | 2 | 2 | ||||||||
MIRT446438 | THYN1 | thymocyte nuclear protein 1 | 2 | 2 | ||||||||
MIRT482781 | STIM1 | stromal interaction molecule 1 | 2 | 2 | ||||||||
MIRT497714 | CYP1A1 | cytochrome P450 family 1 subfamily A member 1 | 2 | 2 | ||||||||
MIRT500907 | STARD13 | StAR related lipid transfer domain containing 13 | 2 | 2 | ||||||||
MIRT503251 | KIF18B | kinesin family member 18B | 2 | 2 | ||||||||
MIRT504750 | TEP1 | telomerase associated protein 1 | 2 | 4 | ||||||||
MIRT512158 | CD164 | CD164 molecule | 2 | 6 | ||||||||
MIRT518043 | LSM3 | LSM3 homolog, U6 small nuclear RNA and mRNA degradation associated | 2 | 4 | ||||||||
MIRT526038 | GMDS | GDP-mannose 4,6-dehydratase | 2 | 2 | ||||||||
MIRT529828 | ARGFX | arginine-fifty homeobox | 2 | 2 | ||||||||
MIRT531808 | POLD3 | DNA polymerase delta 3, accessory subunit | 2 | 2 | ||||||||
MIRT533139 | WNT10A | Wnt family member 10A | 2 | 2 | ||||||||
MIRT538612 | CCT5 | chaperonin containing TCP1 subunit 5 | 2 | 4 | ||||||||
MIRT555617 | PHLPP2 | PH domain and leucine rich repeat protein phosphatase 2 | 2 | 2 | ||||||||
MIRT561705 | PTP4A1 | protein tyrosine phosphatase type IVA, member 1 | 2 | 2 | ||||||||
MIRT562301 | GINM1 | glycoprotein integral membrane 1 | 2 | 2 | ||||||||
MIRT566732 | MSH6 | mutS homolog 6 | 2 | 2 | ||||||||
MIRT569369 | IMPG1 | interphotoreceptor matrix proteoglycan 1 | 2 | 2 | ||||||||
MIRT572314 | HSPB6 | heat shock protein family B (small) member 6 | 2 | 2 | ||||||||
MIRT574602 | LZIC | leucine zipper and CTNNBIP1 domain containing | 2 | 2 | ||||||||
MIRT612023 | FOXF2 | forkhead box F2 | 2 | 2 | ||||||||
MIRT616950 | MAPKAPK2 | mitogen-activated protein kinase-activated protein kinase 2 | 2 | 2 | ||||||||
MIRT624175 | DERL2 | derlin 2 | 2 | 2 | ||||||||
MIRT647634 | FAIM2 | Fas apoptotic inhibitory molecule 2 | 2 | 2 | ||||||||
MIRT659393 | CORO2A | coronin 2A | 2 | 2 | ||||||||
MIRT659955 | CXCL10 | C-X-C motif chemokine ligand 10 | 2 | 2 | ||||||||
MIRT684001 | FOLR1 | folate receptor 1 | 2 | 2 | ||||||||
MIRT688143 | GABPB1 | GA binding protein transcription factor beta subunit 1 | 2 | 2 | ||||||||
MIRT688609 | CYBRD1 | cytochrome b reductase 1 | 2 | 2 | ||||||||
MIRT693583 | SLC39A1 | solute carrier family 39 member 1 | 2 | 2 | ||||||||
MIRT699922 | RUFY2 | RUN and FYVE domain containing 2 | 2 | 2 | ||||||||
MIRT712961 | PET117 | PET117 homolog | 2 | 2 | ||||||||
MIRT723950 | TMEM184A | transmembrane protein 184A | 2 | 2 |
miRNA-Drug Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
miRNA-Drug Resistance Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|